Effects of Antithrombin III in Patients With Disseminated Intravascular Coagulation Diagnosed by Newly Developed Diagnostic Criteria for Critical Illness

Abstract

A study was conducted to test the hypotheses that antithrombin III (antithrombin) improves disseminated intravascular coagulation (DIC) when applied to DIC patients diagnosed by sensitive criteria and that the administration of high-dose antithrombin is a beneficial treatment for DIC. Twenty-three DIC patients diagnosed based on the Japanese Association for Acute Medicine (JAAM) DIC diagnostic criteria were treated with either high-dose (60 IU/kg/day) or low-dose (30 IU/kg/day) antithrombin concentrates for 3 days. The clinical conditions that cause DIC were restricted to systemic inflammatory response syndrome (SIRS) and sepsis. Data of antithrombin activity, platelet counts, coagulation and fibrinolytic markers, and DIC scores before antithrombin administration (day 0), on days 1 to 3, and on day 7 were retrospectively collected from computer-based records. Patients who met the JAAM DIC criteria were administered either high-dose (12 patients) or low-dose (11 patients) antithrombin. The patients’ backgrounds and antithrombin activity (high dose, 51.5 ± 14.5%; low dose, 62.6 ± 19.3%; P = .153) on day 0 were identical in the 2 groups. The JAAM DIC score and prothrombin time ratio on day 7 significantly improved when compared with those on day 0. However, mortality at 28 days as well as interaction within the antithrombin doses administered showed no difference. There were also no differences in the time course of the platelet counts, coagulation and fibrinolytic markers, and DIC scores in the 2 groups. The authors conclude that the effects of antithrombin on prognosis and coagulation and fibrinolytic parameters are independent of the doses administered in patients with SIRS/sepsis-associated DIC.

Keywords

disseminated intravascular coagulation antithrombin III systemic inflammatory response syndrome sepsis diagnosis treatment

References

Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35:2191-2194.

Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.

Gando S. , Kameue T. , Nanzaki S. , Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost. 1996;75:224-228.

Hoots WK Non-overt disseminated intravascular coagulation: definition and pathophysiological implication. Blood Rev. 2002;16 (suppl I):S3-S9.

Gando S. , Iba T. , Eguchi Y. , et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-631.

Levi M. , de Jonge E. , van der Poll T. , ten Cate H. Disseminated intravascular coagulation. Thromb Haemost. 1999;82:695-705.

Wiedermann CJ , Kaneider NC A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis . Blood Coagul Fibrinolysis. 2006;17:521-526.

Kienast J. , Jures M. , Wiedermann CJ , et al. Treatments effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-97.

Gando S. , Saitoh D. , Ogura H. , et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med . 2008;36:145-150.

10.

Knaus WA , Draper EA , Wagner DP , Zimmerman JE APACHE II: a severity classification system. Crit Care Med . 1985;13:818-829.

11.

Vincent JL , de Mendonça A. , Cantraine F. , et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998;26:1793-1800.

12.

Taylor FBJr , Toh CH , Hoots WK , et al. Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation . Thromb Haemost. 2001;86:1327-1330.

13.

Warren BL , Eid A. , Singer P. , et al. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-1878.

14.

Fourrier F. , Jourdain M. , Tournoys A. Clinical results with antithrombin in sepsis . Crit Care Med. 2000;28(9 suppl):S38-S43.

15.

Wada H. , Wakita Y. , Nakase T. , et al. Outcome of disseminated intravascular coagulation in relation to the score when the treatment was begun. Thromb Haemost . 1995;74:848-852.